In Türkiye, a rapid rise in exchange rates and adverse economic developments have led to difficulties in sourcing certain life sciences products on the market, and even caused some pharmaceutical companies to, either partially or fully, withdraw from the Turkish market, or to abandon the decision to introduce new products to the market. Moreover, news of counterfeit products related to the practices of product procurement from abroad have further increased concerns about the reliability of the available products on the market.
It can be said that the healthcare industry regulation in Türkiye, in particular licensing, registration systems, ethics, and compliance rules are in line with the standards of developed countries and EU legislation.
Last year, the Turkish Medicines and Medical Devices Agency (“Agency”), established under the Ministry of Health (“Ministry”), and the Social Security Institution (“SSI”) have started to take several additional measures to ensure the continuity of the supply of products to the market.
With this paper, we outline the most up-to-date issues in life sciences.
CONTENTS
- The Use of Cannabis in Pharmaceutical Production
- Food Supplements
- Application Fee for Scientific Meetings of Pharmaceuticals and Medical Devices Has Been Introduced
- Developments in the Field of Medical Devices
- Interactions with HCPs, Transfer of Values and Payments
- Named Patient Program
- Market Availability of Products and Parallel Trade
- Market Access- Alternative Reimbursement Models
- Pricing of Pharmaceuticals and the Fixed Exchange Rate
